The current approach to drug discovery is hypotheses driven, and combination therapies have preset biasness from a few factors such as mechanisms of actions, literature reviews and scientific panels. This results in one lead molecule usually only being tested with one to two other drugs for particular indications. The team holds IP that allows assessment of hundreds of drugs with lead molecules that are tested and validated against multiple indications through a proprietary AI platform. This platform, combined with automated experiments and proprietary arrays, allows for optimal drug discovery more effectively and efficiently.
The technology is also applicable for media formulation, whereby optimal media for bio-processes/cell culture can be designed using the platform.
The technology is a combination of a proprietary AI platform, automated experiments and proprietary array design. The platform allows for identification of optimal combination therapies and media conditions in a much faster and cost-effective manner. The team was able to demonstrate results with significantly fewer number of experiments relative to traditional high throughput screening.
The platform is applicable for both in vitro and in vivo research studies.
Customers (biotech/pharmaceutical/healthcare companies) benefit in a few ways: